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Background: Cisplatin is a potent chemotherapeutic agent, but its nephrotoxicity, which results in acute kidney injury
(AKI), often limits its clinical application. Although many studies have attempted to target the mechanism responsible
for its nephrotoxicity, no such method has been demonstrated to be effective in clinical trials. Recently, a dipeptidyl
peptidase-4 (DPP4) inhibitor has been reported to have a renoprotective effect in a mouse model of cisplatin-induced
AKI. Therefore, we will evaluate whether a DPP4 inhibitor protects the kidney from cisplatin-induced injury in humans.
Methods/Design: This is a single-center, prospective, randomized, double-blind, placebo-controlled trial. A total
of 182 participants who are scheduled for cisplatin treatment will be enrolled and randomly assigned to receive
either a DPP4 inhibitor (gemigliptin) or a placebo. Participants will take the study drugs for 8 days starting 1
day before cisplatin treatment. The primary outcome of interest is the incidence of AKI at 7 days after finishing
treatment with cisplatin. The secondary outcomes include changes in serum creatinine levels and estimated
glomerular filtration rates from baseline to 7 days after cisplatin treatment.
Discussion: This is the first clinical trial to investigate the effect of a DPP4 inhibitor on cisplatin-induced AKI.
Trial registration: ClinicalTrials.gov number NCT02250872, December 26, 2014.
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Cisplatin is a potent chemotherapeutic agent that is ap-
proved for the treatment of several types of cancer, in-
cluding bladder cancer, cervical cancer, non-small cell
lung cancer, and squamous cell carcinoma of the head
and neck [1]. However, the kidneys are particularly
affected by cisplatin because it accumulates there [1].
Cisplatin nephrotoxicity is manifested by hypokalemia,
hypomagnesemia, and acute kidney injury (AKI), which
often limit its clinical use [1–4]. Impairment of renal
function is common and dose-dependent. AKI is found
in 6–35 % of patients treated with a single dose of
cisplatin and in 50–75 % of patients treated with mul-
tiple doses [5–7].* Correspondence: kyna@snubh.org
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unless otherwise stated.Abnormal renal hemodynamics and renal tubular cell
toxicity resulting from oxidative stress, apoptosis, and
inflammation are considered to be the mechanisms of
cisplatin-induced nephrotoxicity [1, 8–14]. Different
strategies targeting each mechanism of nephrotoxicity
have been evaluated for their abilities to prevent and/or
attenuate renal injury [1, 15, 16]. However, none of these
strategies has been demonstrated to be effective in clin-
ical trials [15].
Dipeptidyl peptidase-4 (DPP4) inhibitors are currently
used in the treatment of type 2 diabetes mellitus to im-
prove glucose tolerance by increasing the half-lives of
glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic peptide [17, 18]. However, in addition to
the glucose-lowering effects of DPP4 inhibitors, tissue-
protective effects of DPP4 inhibition have been also
demonstrated [19–23]. In particular, studies have shown
that DPP4 inhibitors can protect the kidney from
diabetic nephropathy, ischemia-reperfusion injury, andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have reported that a DPP4 inhibitor has a renoprotective
effect in rodent cisplatin-induced AKI models by enhan-
cing GLP-1 signaling [29]. Based on these reports of the
effects of DPP4 inhibitors, we hypothesize that treat-
ment with a DPP4 inhibitor will have a beneficial effect
in cisplatin-induced AKI.




Treatment with a DPP4 inhibitor will prevent and/or
ameliorate cisplatin-induced AKI in humans. Compared
with placebo-treated patients, the incidence of AKI will
be lower in DPP4 inhibitor-treated patients.
Study design
This is a single-center, prospective, randomized, double-
blind, placebo controlled study. This study is an
investigator-initiated clinical trial. The study algorithm is
described in Fig. 1. After enrollment, clinical follow-up
will be performed 7 days after cisplatin treatment.
Study participants and measurements
Cancer patients aged 18–70 years treated with intraven-
ous cisplatin will be screened. The following will be con-
ducted at the initial visit: (1) a questionnaire regarding
active cancer history, chemotherapy, medical history,
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Fig. 1 Study algorithmnonsteroidal anti-inflammatory drugs (NSAIDs), antibi-
otics, contrast media, and calcineurin inhibitors; (2) a
physical examination of all systems; (3) height and
weight measurements; (4) blood pressure and pulse rate
measurements. Participants who meet all of the inclu-
sion and exclusion criteria and provide written, informed
consent are eligible for this study (Table 1).
Serum creatinine (SCr) will be measured by the isotope
dilution mass spectrometry-traceable method using a
Toshiba TBA 200FR Analyzer (Toshiba, Tokyo, Japan).
The estimated glomerular filtration rate (eGFR) will be
calculated using the Chronic Kidney Disease Epidemi-
ology Collaboration equations (CKD EPI). The CKD EPI
formula, expressed as a single equation, is eGFR = 141 ×
min (SCr/κ, 1)α × max (SCr/κ, 1)-1.209 × 0.993Age × 1.018
[if female] × 1.159 [if black], where κ is 0.7 for females
and 0.9 for males, α is −0.329 for females and −0.411 for
males, min indicates the minimum of SCr/κ or 1, and max
indicates the maximum of SCr/κ or 1 [30] .
Randomization
A research coordinator will conduct the randomization
and deliver the study drug. The participants and investi-
gators will be blinded to the treatment assignment. A list
of random numbers will be generated by an independent
statistician. Eligible participants will be randomly
assigned 1:1 to either the treatment group or the control
group in accordance with the predefined randomization
list with a block size of four. The randomization will be
stratified on the basis of the number of times cisplatin istin assessed for eligibility 
Excluded
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age between 18 and 70 Diabetes mellitus
Chronic kidney disease stage
IV-V (eGFR <30 ml/min/1.73m2)
History of transplantation





Use of other nephrotoxic agents
such as nonsteroidal anti-inflammatory
drugs, aminoglycosides, colistin,
vancomycin, cyclosporine, tacrolimus
Receiving contrast media during last 72 h
Liver disease (bilirubin >2 mg/dl,
transaminase levels >2.5 times the
upper limit normal)
Written consent Patients with high risks of dehydration
owing to poor oral intake
High blood pressure (>180/110 mmHg
despite antihypertensive medications)
Hypersensitivity to gemigliptin or its
excipients
Low compliance to gemigliptin treatment
Abbreviation: eGFR estimated glomerular filtration rate
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platin dose (< or ≥50 mg/m2) and will utilize a random-
ized block design.
Treatments
A selective DPP4 inhibitor, gemigliptin, which is clin-
















Fig. 2 Study schedule. Abbreviations: R, randomization; Wt, weight; Ht, heig
aminotransferase; ALT, alanine aminotransferase; chol, cholesterol; BUN, bloo
dipeptidyl peptidase 4gemigliptin and placebo tablets will be provided by LG
Life Sciences (Seoul, Korea). After randomization, the
participants will take either a gemigliptin (treatment
group) or placebo (control group) pill for 8 days start-
ing 1 day before cisplatin treatment. The tablet shapes
and packaging of the placebo pills are identical to
those of the gemigliptin pills. The prescription and ad-
ministration of the study drugs will be conducted in a
double-blind manner. Based on a study that reported
a renoprotective effect of a DPP4 inhibitor in a mouse
model of cisplatin-induced AKI [29], 100 mg/day of
gemigliptin will be administered to the participants in
two divided doses for 8 days starting 1 day before cis-
platin treatment (Fig. 2). The administration of other
nephrotoxic drugs, such as NSAIDs, aminoglycosides,
colistin, and vancomycin, will be prohibited during the
study, and exposure to contrast media during the 72 h
prior to treatment will result in exclusion from the
study. Investigators or research coordinators will
evaluate drug compliance by counting pills, and par-
ticipants with less than 80 % compliance will be re-
moved from the study.Chemotherapy regimen and precautions
A hydration protocol will be identically applied to both
the treatment and control groups. Cisplatin will be
mixed with 500 ml of isotonic saline and will be infused
into each patient over 30 min. Participants treated
with ≥50 mg/m2 of cisplatin will receive 2,000 ml of
0.45 % saline and 100 ml of 15 % mannitol. Partici-
pants treated with <50 mg/m2 of cisplatin will receive
1,000 ml of 0.45 % saline (Table 2).emigliptin 50mg bid
Placebo




DPP4 activity, DPP4 
inhibitor concentration 
Follow-up  lab 
Day 7 (+1-2 day)
ht; BP, blood pressure; CBC, complete blood count; AST, aspartate
d urea nitrogen; Cr, creatinine; tCO2, total CO2; U/A, urinalysis; DPP4,
Table 2 Hydration protocol
Cisplatin dose Before and after cisplatin
infusion
During cisplatin infusion
≥50 mg/m2 2,000 ml of 0.45 % saline with
100 ml of 15 % mannitol
Mix cisplatin in 500 ml
of isotonic saline
<50 mg/m2 1,000 ml of 0.45 % saline Mix cisplatin in 500 ml
of isotonic saline
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The primary outcome of interest is the incidence of AKI
at 7 days after cisplatin treatment, where AKI is defined
as any of the following: an increase in SCr levels of ≥0.3
mg/dl, an increase in SCr levels of 50 % compared with
baseline levels, or a decrease in the eGFR by ≥25 % com-
pared with baseline [31–33]. The secondary outcomes
will include changes in SCr levels and the eGFR com-
pared with baseline values for 7 days after cisplatin
treatment.
Clinical and laboratory evaluations
The physical examination and medication reviews will
be conducted before and after 8 days of treatment. La-
boratory evaluations will be performed twice, before and
after 8 days of treatment; the laboratory evaluations will
include a complete blood count; measurements of the
levels of hemoglobin, electrolytes, SCr, calcium, phos-
phorous, protein, albumin, and glucose; a liver function
test; and urinalysis. DPP4 activity and the concentration
of the DPP4 inhibitor will be measured in serum and
plasma after treatment.
Safety issues
Any occurrence of headache, diarrhea, upper respiratory
tract infection, hypoglycemia, or hypersensitivity reac-
tion will be recorded during treatment with gemigliptin/
placebo. All adverse events, including serious adverse
events, will be recorded and followed up during the
study period or until resolution. All serious adverse
events will be graded and reported to investigators and
the ethics committee.
Sample size calculations
No previous study has evaluated the effect of a DPP4 in-
hibitor on cisplatin-induced AKI. We expect that the in-
cidence of AKI will be 25 % in patients treated with a
single dose of cisplatin and that treatment with a DPP4
inhibitor could reduce this incidence by 60 %. We calcu-
lated the required sample size for an estimated dropout
rate of 20 %, a one-sided level of significance of α = 5 %,
and a power of 80 % and found that 91 participants will
be needed in each group to find a significant difference
using a χ2 test. A total of 182 participants will be
included in the analysis.Statistical analyses
Statistical analyses will be conducted on both per proto-
col (PP) and intention-to treat (ITT) bases. For the PP
analysis, all participants who completed the study will be
included to evaluate the primary and secondary out-
comes. For the ITT analysis, all participants who were
enrolled and randomized to one of the two groups will
be included.
The baseline characteristics and laboratory data will be
presented as the means and standard deviations for con-
tinuous variables and as frequencies and percentages for
categorical variables. The incidence of AKI will be com-
pared between the two groups using a χ2 test. The differ-
ences in changes in SCr levels and in the eGFR will be
analyzed using Student’s t-test or the Mann-Whitney U
test. A value of P < 0.05 will be considered statistically
significant. All analyses will be performed using SPSS
Statistics software V21.0 (IBM Corporation, Armonk,
NY, USA).
Ethical approval
The study will be performed in accordance with the
Declaration of Helsinki, as amended by the 64th World
Medical Association General Assembly in 2013. All of
the participants will provide written, informed consent
stating that participation is voluntary and can be with-
drawn at any time. This study was approved by the Insti-
tutional Review Board of the Seoul National University
Bundang Hospital (B-1408/264-002). The trial protocol
has been registered at http://www.clinicaltrials.gov
(NCT02250872).
Discussion
Cisplatin is an effective anti-tumor drug whose clinical
application is limited by its nephrotoxicity [1, 8]. Con-
ventional renoprotective measures in patients receiving
cisplatin are not satisfactory. Many studies have investi-
gated the effects of protective strategies targeting the
molecular mechanisms of cisplatin toxicity. Although
encouraging results have been found in in vitro and
in vivo models, a lack of positive data in clinical trials
has prevented the effective clinical application of these
strategies [1, 15, 16]. DPP4 inhibitors, which are anti-
diabetic drugs, have been shown to protect various
organs from injuries [19–29]. This trial is the first to in-
vestigate whether a DPP4 inhibitor protects the kidney
from cisplatin-induced injury in humans.
Previous studies have reported that cisplatin-induced
AKI occurred in 6–35 % of patients within 7 days after a
single dose of cisplatin [1, 5, 6, 31] and resolved within
15 days [7]. The incidence of AKI in patients treated
with a single dose of cisplatin was 14.4 % at our institu-
tion. The average follow-up time was 17 days. However,
the incidence of AKI would be higher than 14.4 % if we
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treatment; we estimate that the incidence of AKI would
be approximately 25 %. We tentatively suggest that treat-
ment with a DPP4 inhibitor could result in a 60 % re-
duction in the risk of AKI. The statistical power may be
compromised if sample size is calculated using a one-
sided level instead of a two-sided level. However, this
trial is a phase II exploratory research, not a phase III or
IV study on the possibility of direct clinical application.
In addition, from the previous study [29], it is expected
that DPP4 inhibitors will ameliorate rather than have no
impact on or exacerbate cisplatin-induced AKI. It is not
feasible to enroll more participants in our institution
even though this study will be extended. Nevertheless,
based on our assumptions, the sample size required for
this study is larger than that of previous clinical studies
of cisplatin-induced nephrotoxicity [15, 34–38].
We have considered the potential interactions between
gemigliptin and cisplatin from the beginning of this
study. First, cisplatin has no effect on hepatic cyto-
chrome P450 3A4 (CYP3A4) in human liver microsomes
[39], while gemigliptin is largely metabolized by CYP3A4
[40]. Second, cisplatin is mainly excreted by the kidney,
and its nephrotoxicity is mediated via organic cation
transporter 2 (OCT2) in the kidney [1, 41]. Gemigliptin
and its active metabolite, LC15-0636, are very weak in-
hibitors of OCT2 in cultured xenopus oocytes. In terms
of metabolic pathways and the renal transport system,
cisplatin and gemigliptin never interact. Therefore, the
renoprotective effect of gemigliptin could be investigated
without affecting the anti-tumor activity of cisplatin.
The dose of gemigliptin in this study is two times
higher than the dose used in the treatment of diabetes.
Based on previous studies [29, 42], we determined that
this dose was necessary to inhibit DPP4 activity by more
than 80 % during cisplatin exposure.
DPP4 inhibition has not caused hypoglycemia in stud-
ies of healthy volunteers [43, 44]. Because the effects of
GLP-1 on insulin secretion are glucose-dependent, the
risk of hypoglycemia associated with DPP4 inhibitor
treatment is low [45]. Nonetheless, we will exclude the
participants with diabetes from this study. Therefore, the
risk of hypoglycemia due to gemigliptin administration
may be almost negligible in this trial.
A strength of this trial is that we will standardize hy-
dration protocols before, during, and after cisplatin
treatment to minimize the effects of confounding vari-
ables associated with renal outcomes. Cisplatin dosage
per body surface area and the presence of diabetes have
been reported to be the risk factors for moderate and se-
vere cisplatin-induced AKI [31]. Another strength of this
study is that randomization will be stratified on the basis
of cisplatin dosage. Furthermore, participants with dia-
betes will be excluded from this study.A small number of trials have investigated the clinical
use of DPP4 inhibitors in the treatment of conditions
other than diabetes. Treatments with DPP4 inhibitors
have been investigated for their ability to enhance en-
graftment following umbilical cord blood transplantation
in adults with hematologic malignancies [46], to improve
endothelial dysfunction, and to prevent major cardiovas-
cular events in patients with type 2 diabetes [47–49].
Again, we emphasize the originality of this trial, which
will investigate the effect of a DPP4 inhibitor on
cisplatin-induced AKI.
A limitation of this study is the diversity among the
study participants and chemotherapeutic agents. Patients
with different types of cancer receiving various antican-
cer drugs will be enrolled in this study. We expect that
patients with gastric, biliary, head and neck, and lung
cancer will be enrolled in this study. The following che-
motherapeutic agents are used together with cisplatin in
the treatment of these cancers: capecitabine, tegafur, do-
cetaxel, pemetrexed, etoposide, irinotecan, and gemcita-
bine. All of these agents have been reported to have a
low risk of AKI [50].
In summary, the present study is the first prospective,
randomized controlled trial to evaluate the effect of a
DPP4 inhibitor on cisplatin-induced AKI. The aim of
this study is to demonstrate whether treatment with a
DPP4 inhibitor, gemigliptin, can reduce the incidence of
cisplatin-induced AKI in patients receiving cisplatin.
Trial status
This trial is ongoing. Participants are currently being
recruited.
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